Drug Type CAR-T |
Synonyms Anti BCMA CAR T cell therapy (Hrain Biotechnology), BCMA-CART, Human BCMA Targeted T Cells (Hrain Biotechnology) + [2] |
Target |
Action modulators |
Mechanism BCMA modulators(B-cell maturation protein modulators), T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationBreakthrough Therapy (China) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Myeloma | Phase 2 | China | 12 Jul 2022 | |
Refractory Multiple Myeloma | Phase 1 | China | 08 Jul 2019 | |
Relapse multiple myeloma | Phase 1 | China | 08 Jul 2019 | |
BCMA Positive Multiple Myeloma | Phase 1 | China | 01 Jul 2019 |